As our COVID-19 knowledge and therapy options progress, it is important to remain up to date on methods of prevention. We are now carrying bivalent boosters! These new shots have coverage for the omicron strain of COVID-19, which was NOT covered in the original boosters. Most of our locations offer both Pfizer and Moderna, but you can safely and effectively receive either vaccine, regardless of previous doses.
Moose Pharmacy also offers Evusheld, a combination of monoclonal antibodies that provides long-acting immunity to COVID-19.
Evusheld is a good option for anyone with a severe allergy to ingredients of the vaccine, and/or anyone with a condition that causes a suppressed immune system. These conditions include HIV/AIDS, organ transplant, or anyone taking medications that suppress their immune system such as high dose steroids, tacrolimus, cyclosporine, mycophenolate, etc.
The ingredients of Evusheld (tixagevimab and cilgavimab) are different than the vaccines’ ingredients, so there is a low chance one will also be allergic to Evusheld. In clinical trials, less than 0.1% of patients who received Evusheld experienced a severe allergic reaction.
It is recommended because conditions that suppress the immune system do not allow the body to form a full response to the vaccines, leaving one unprotected against the virus. Evusheld blocks the COVID virus in your body entirely from causing illness, so there is no immune response needed to be protected from the virus.
Those who are at least 12 years old, weigh more than 88 pounds, and meet one of the criteria listed above (allergy or suppressed immune system) should receive Evusheld to prevent getting the COVID-19 virus.
Evusheld is administered as two injections into the muscles of your glutes, and it is currently recommended to receive a dose every 6 months.
We are dedicated to providing the highest quality pharmacy services to our patients.
We want each patient’s visit to be even better than expected.
We believe we have only one reason for existing, and that is to serve our patients.